Team includes Peter Kowey, pioneer of anti-arrhythmic drugs/devices in U.S., and Eric Topol, one of top 10 cited biomedical researchers over past
SAN FRANCISCO, March 3 /PRNewswire/ -- IBC Conference -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the clinical advisory team for its new anti-arrhythmic compound, HBI-3000. The new compound is set to begin enrollment under the final Phase I clinical trial protocol after successful completion of three previous Phase I protocols in China. The advisory team consists of world-class biomedical researchers who will provide guidance to HUYA and its Chinese partner, Shanghai Institute of Materia Medica (SIMM), throughout the course of an innovative U.S./China co-development process for HBI-3000.
The advisory team consists of:
Peter R. Kowey, M.D., Professor of Medicine and Clinical Pharmacology at Jefferson Medical College and a pioneer in the development of many anti-arrhythmic drugs and anti-tachycardia devices;
Eric Topol, M.D., Chief Academic Officer for Scripps Health, former chairman of Cardiovascular Medicine at the Cleveland Clinic for 15 years and recognized by the Institute of Scientific Information as one of the top 10 cited researchers in medicine over the past decade;
Benedict R. Lucchesi, Ph.D., Professor of Pharmacology at the University of Michigan Medical School Department of Pharmacology for more than 40 years and contributor to more than 370 publications in basic pharmacology and drug development;
Denis Roy, M.D., Montreal Heart Institute, Professor and Chair of the Department of Medicine at the University of Montreal and Principal Investigator of the recently completed Atrial Fibrillation and Congestive Heart Failure multi-center international trial;
Jefferson L. Anderson, M.D., Professor of Medicine, University of Utah
and Chief of Cardiology,
|SOURCE HUYA Bioscience International|
Copyright©2008 PR Newswire.
All rights reserved